Current and prospective clinical applications of autoantibodies associated with paraneoplastic neurological syndromes
10.3760/cma.j.cn114452-20230922-00158
- VernacularTitle:神经系统副肿瘤综合征相关自身抗体的临床应用现状与前景展望
- Author:
Zhou BAI
1
;
Yudong LIU
Author Information
1. 北京医院 国家老年医学中心，国家卫生健康委北京老年医学研究所，国家卫生健康委老年医学重点实验室，中国医学科学院老年医学研究院，北京100730
- Keywords:
Paraneoplastic neurological syndromes;
Antibodies;
Diagnosis;
Treatment;
Prognosis
- From:
Chinese Journal of Laboratory Medicine
2023;46(11):1145-1148
- CountryChina
- Language:Chinese
-
Abstract:
Paraneoplastic neurological syndrome (PNS) is an autoimmune syndrome involving the nervous system caused by tumors through distant effects. The diagnosis of PNS is difficult, and PNS-associated autoantibodies are crucial for disease diagnosis, classification, and individualized treatment. PNS-associated autoantibodies are classified into high-, intermediate-, and low-risk antibodies based on their predictive risk of tumors. Their laboratory detection is mainly carried out through indirect immunofluorescence, immunohistochemical analysis, immunoblotting, and other methods. The correct application and interpretation of antibody detection results is crucial for the diagnosis and treatment of PNS. This article reviews the current status and future prospects of the clinical application of autoantibodies related to PNS.
